肠促胰素对不同BMI的2型糖尿病合并代谢性肝病临床疗效  

Clinical Effect of Incretin on Different BMI in T2DM with Metabolic Liver Disease

作　　者：潘焕峰[1] 包塔娜[1] 齐月[1] Pan Huanfeng;Bao Tana;Qi Yue(Jilin People＇s Hospital,Jilin 132001,China)

机构地区：[1]吉林市人民医院,吉林吉林132001

出　　处：《北华大学学报（自然科学版）》2018年第6期768-772,共5页Journal of Beihua University（Natural Science）

基　　金：吉林市医疗卫生指导性计划项目(201737168)

摘　　要：目的观察肠促胰素治疗不同体质指数(BMI)的初诊2型糖尿病(T2DM)合并代谢性肝病(NAFLD)的临床疗效.方法 108例患者按(BMI)分为3组,经24周的肠促胰素治疗,观察患者体质量、BMI、糖化血红蛋白、空腹血糖、空腹胰岛素水平、胰岛素抵抗指数、甘油三酯、谷丙转氨酶及肝脏超声积分的变化.结果肠促胰素在治疗合并NAFLD的初诊T2DM临床疗效显著,体质量、BMI、肝脏超声积分显著降低,糖化血红蛋白、空腹血糖、谷丙转氨酶、甘油三酯均较治疗前降低,差异具有统计学意义(P<0.05);胰岛素抵抗减轻,NAFLD改善情况与治疗前(BMI)相关(χ~2=9.902,P=0.042).结论肠促胰素对不同(BMI)合并NAFLD患者的临床疗效显著,且(BMI)越高疗效越佳,在应用肠促胰素治疗后,NAFLD得到明显改善,多重代谢异常也得到改善.Objective To observe the clinical effect of incretin on newly diagnosed type 2 diabetes mellitus（T2DM） and metabolic liver disease （NAFLD） with different body mass index （BMI）. Method 108 patientswere divided into three groups according to BMI. All patients were treated with incretin therapy. After 24 weeks,body weight, BMI, HbA1c, FPG, FINS, HOMA-IR, TG, and ALT, as well as liver ultrasound integral wereobserved and analyzed. Results The clinical effect was significantly better in patients newly diagnosed T2DMwith NAFLD after treatment with incretin. There was a significant reduction in body weight,BMI,liver ultrasoundintegral. In addition,HbA1c,FPG,ALT,TG levels were significantly decreased post treatment（P〈0. 05）. Theinsulin resistance was also reduced. The improvement of NAFLD was related to pretreatment BMI （ χ2= 9. 902,P = 0. 042）. Conclusion The clinical curative effect of incretin differed significantly based on BMI in T2DMand NAFLD. Treatment of incretin on patients with higher BMIs, is associated with better improvement inmetabolic abnormalities caused by T2DM and NAFLD.

关 键 词：2型糖尿病 代谢性肝病 胰岛素抵抗 体质指数 

分 类 号：R587.1[医药卫生—内分泌]